DR REDDYS LABORATORIES LTD (RDY)
Q3 2026Earnings receipt·reported Oct 23, 2026·quarter ended Sep 30, 2026
Rev Beat +0.8%
The street expected
EPS consensus
$0.16
1 analyst · street range $0.16 – $0.16
Revenue consensus
₹86.02B
22 analysts
Year-ago EPS
$0.19
same basis as the consensus row
frozen Oct 23, 2026 — before the print erased it
The company printed
EPS (GAAP)
₹11.10
Revenue
₹86.71B
Revenue vs street
+0.8%
against ₹86.02B — stockanalysis consensus, pre-report snapshot
verified from the wire release · figures published 4:10 PM ET
The next-quarter bar, as it stood at the print
$11.79 adj EPS₹89.85B revenuefor the quarter ending Dec 31, 2026 · 5 analysts
any guidance in this release was set against this baseline — it rolls forward and vanishes once the street re-models
Consensus into the print
The street walked down the bar from $0.17 (Jul 18, 2026) to $0.16 the night before the print.
Jul 18, 2026Oct 23, 2026
Why this page exists
Every public surface destroys the “expected” number at the moment it matters: the actual overwrites it, and post-hoc surprise figures get computed against restated consensus. This receipt was frozen from Wall St Engine’s nightly expectation archive before the print and joined to figures verified from the release itself. It does not update, and it cannot be reconstructed after the fact.
receipt frozen 2026-10-23 20:10 UTC · RDY company page